MX2013002409A - Antagonistas del receptor 5-ht2b. - Google Patents

Antagonistas del receptor 5-ht2b.

Info

Publication number
MX2013002409A
MX2013002409A MX2013002409A MX2013002409A MX2013002409A MX 2013002409 A MX2013002409 A MX 2013002409A MX 2013002409 A MX2013002409 A MX 2013002409A MX 2013002409 A MX2013002409 A MX 2013002409A MX 2013002409 A MX2013002409 A MX 2013002409A
Authority
MX
Mexico
Prior art keywords
ht2b receptor
receptor antagonists
ht2b
medicine
prevention
Prior art date
Application number
MX2013002409A
Other languages
English (en)
Spanish (es)
Inventor
Donck Luc August Laurentius Ver
Johannes Wilhelmus John F Thuring
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2013002409A publication Critical patent/MX2013002409A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2013002409A 2010-09-01 2011-08-30 Antagonistas del receptor 5-ht2b. MX2013002409A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10174880 2010-09-01
PCT/EP2011/064906 WO2012028614A1 (en) 2010-09-01 2011-08-30 5-ht2b receptor antagonists

Publications (1)

Publication Number Publication Date
MX2013002409A true MX2013002409A (es) 2013-04-03

Family

ID=43127285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002409A MX2013002409A (es) 2010-09-01 2011-08-30 Antagonistas del receptor 5-ht2b.

Country Status (14)

Country Link
US (2) US8703958B2 (OSRAM)
EP (1) EP2619180B1 (OSRAM)
JP (1) JP5845263B2 (OSRAM)
KR (1) KR101815123B1 (OSRAM)
CN (1) CN103080089B (OSRAM)
AU (1) AU2011298361B2 (OSRAM)
BR (1) BR112013004503A2 (OSRAM)
CA (1) CA2806647C (OSRAM)
EA (1) EA020967B1 (OSRAM)
ES (1) ES2525515T3 (OSRAM)
MX (1) MX2013002409A (OSRAM)
SG (1) SG188233A1 (OSRAM)
WO (1) WO2012028614A1 (OSRAM)
ZA (1) ZA201301561B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2619180B1 (en) 2010-09-01 2014-10-08 Janssen Pharmaceutica, N.V. 5-ht2b receptor antagonists
CN103467596A (zh) * 2012-06-06 2013-12-25 北京大学 一个治疗肺动脉高压的新靶点
WO2015134503A1 (en) * 2014-03-04 2015-09-11 The Children's Hospital Of Philadelphia Methods for managing care of patients predisposed to progressive mitral valve diseases
CN110950843B (zh) * 2019-11-28 2022-12-27 广东东阳光药业有限公司 取代的苯酰胺衍生物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
GB8519707D0 (en) * 1985-08-06 1985-09-11 Fordonal Sa Chemical compounds
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
CA2410939C (en) * 2000-06-07 2010-02-16 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
CN1918157B (zh) * 2004-01-07 2010-06-23 ARYx医疗有限公司 立体异构化合物及治疗胃肠道和中枢神经系统紊乱的方法
EP1991545A2 (en) 2005-12-23 2008-11-19 AstraZeneca AB Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
WO2008139152A1 (en) * 2007-05-11 2008-11-20 Sentinel Oncology Limited N-oxide-containing pharmaceutical compounds
EP2619180B1 (en) 2010-09-01 2014-10-08 Janssen Pharmaceutica, N.V. 5-ht2b receptor antagonists

Also Published As

Publication number Publication date
US8703958B2 (en) 2014-04-22
CA2806647A1 (en) 2012-03-08
CA2806647C (en) 2018-09-18
ZA201301561B (en) 2014-08-27
AU2011298361B2 (en) 2014-03-13
EP2619180B1 (en) 2014-10-08
EA201390312A1 (ru) 2013-07-30
KR20130101503A (ko) 2013-09-13
CN103080089A (zh) 2013-05-01
KR101815123B1 (ko) 2018-01-04
US20140187585A1 (en) 2014-07-03
SG188233A1 (en) 2013-04-30
US20130172386A1 (en) 2013-07-04
WO2012028614A1 (en) 2012-03-08
JP2013536823A (ja) 2013-09-26
AU2011298361A1 (en) 2013-02-14
US9139523B2 (en) 2015-09-22
JP5845263B2 (ja) 2016-01-20
BR112013004503A2 (pt) 2016-06-07
ES2525515T3 (es) 2014-12-23
EA020967B1 (ru) 2015-03-31
EP2619180A1 (en) 2013-07-31
HK1182097A1 (zh) 2013-11-22
CN103080089B (zh) 2015-09-23

Similar Documents

Publication Publication Date Title
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
MX354102B (es) Derivados de bencimidazol-prolina.
MX2013004307A (es) Derivados de arilamida como bloqueadores de ttx-s.
WO2012032209A3 (es) Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora.
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
WO2013169574A3 (en) Aliphatic spirolactam cgrp receptor antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
CL2014000504A1 (es) Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
AU2011234398A8 (en) Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
CL2014001779A1 (es) Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades.
UA102857C2 (en) Quinuclidine carbonate derivatives and use thereof
TN2011000282A1 (en) Alkaloid aminoester derivatives and medicinal composition thereof
PH12015501339A1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
WO2010144477A3 (en) Sulfonylurea modulators of endothelin receptor
CL2014002048A1 (es) Compuestos derivados de 4-(benzoimidazol-2-il)-tiazol y derivados aza relacionados; composicion farmaceutica; y uso en la prevencion y el tratamiento de trastornos autoinmunes, inflamatorios, enfermedades infecciosas, entre otras.
MX2010009574A (es) 2-aminoquinolinas.
WO2011138265A3 (en) Indole and indazole derivatives as orexin receptor antagonists
EA201290229A1 (ru) Производные спиролактама и их применение
MX2013002409A (es) Antagonistas del receptor 5-ht2b.
WO2009128661A3 (ko) 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2011091410A8 (en) Trpv4 antagonists
WO2010131192A3 (en) Novel oxazolidinone derivatives and their use as orexin receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration